HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) has started a phase IIb/III study for its surufatinib candidate, HMPL-012, an oral small-molecule angio-immuno kinase inhibitor that can simultaneously block tumor angiogenesis and immune evasion.